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Here we provide recommendations for the use of viral vaccines in anticipation of the 2014 southern hemisphere influenza season. For a 
review of the 2013 influenza season, please refer to the National Institute for Communicable Diseases, National Health Laboratory Service 
website (http://www.nicd.ac.za).
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Recommended vaccine 
formulation
The following strains have been recommended by the 
World Health Organization (WHO)[1] for the 2014 
southern hemisphere influenza season:
• A/California/7/2009 (H1N1)pdm09-like virus (A/Christchurch/
16/2010 is an A/California/7/2009-like virus)
• A/Texas/50/2012 (H3N2)-like virus (A/Texas/50/2012 is an
A(H3N2) virus that, following adaptation to growth in eggs, 
has maintained antigenic properties similar to the majority of 
recently circulating cell-propagated A(H3N2) viruses including A/
Victoria/361/2011)
• B/Massachusetts/2/2012-like virus.
Vaccines should contain 15  μg of each haemagglutinin antigen in 
each 0.5 ml dose.
Indications
• Persons (adults or children) who are at high risk for influenza
and its complications because of underlying medical conditions 
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and who are receiving regular medical care for conditions such as 
chronic pulmonary and cardiac diseases, chronic renal diseases, 
diabetes mellitus and similar metabolic disorders; individuals who 
are immunosuppressed (including HIV-infected persons with 
CD4+ counts >100  cells/µl); individuals who are morbidly obese 
(body mass index ≥40 kg/m2)
• Pregnant women – irrespective of stage of pregnancy
• Residents of old-age homes, chronic care and rehabilitation
institutions
• Children on long-term aspirin therapy
• Medical and nursing staff responsible for the care of high-risk cases
• Adults and children who are family contacts of high-risk cases
• All persons >65 years of age
• Any persons wishing to protect themselves from the risk of
contracting influenza, especially in industrial settings where large-
scale absenteeism could cause significant economic losses.
Dosage
• Adults: Whole or split-product or subunit vaccine: one dose
intramuscularly (IM)
• Children (<12 years of age): Split-product or subunit vaccine: one
dose IM
• Children (<9 years of age) who have never been vaccinated: two
doses, 1 month apart
• Children (<3 years of age): Half the adult dose on two occasions
separated 1 month apart
• The influenza vaccine is not recommended for infants <6 months
of age.
Contraindications
• Persons with a history of severe (anaphylactic) hypersensitivity to
eggs or other components of the vaccine
• Persons with acute febrile illnesses should preferably be immunised 
after symptoms have disappeared.
Timing
Vaccines should be given sufficiently early to provide protection for 
the winter. A protective antibody response takes about two weeks to 
develop.
Antiviral chemotherapy
At present, influenza A (H1N1) pdm09 and H3N2, and influenza B 
viruses remain sensitive to oseltamivir (and zanamivir). The dosages 
for treatment and post-contact prophylaxis (where indicated) are 
provided in Table 1.
Antiviral chemoprophylaxis
Antiviral chemoprophylaxis for the contacts of persons infected 
with influenza is currently not recommended. Recent WHO 
recommendations advise presumptive treatment using the treatment 
regimen described above for higher-risk individuals (patients with 
severe immunosuppression or transplant patients) exposed to 
influenza instead of the previously recommended long-term lower-
dose chemoprophylaxis regimen. These higher-risk individuals need 
to be carefully monitored during the influenza season for early signs 
and should then be treated immediately on suspicion of infection.
For a more detailed description of antiviral management and 
chemoprophylaxis of influenza, please refer to the National Institute 
for Communicable Diseases Healthcare Workers Handbook on 
Influenza.[2]
For the full report on recommended influenza vaccines, refer to the 
WHO recommendations.[1]
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Table 1. Recommended dosage of antiviral agents for 
treatment
Age group
Dosage*
Oseltamivir Zanamivir
Adults 75 mg td 2 × 5 mg inhalations 
(10 mg total) td 
Premature neonates 1 mg/kg td -
Infants  (0 - 12 months) 3 mg/kg td -
Children, weight (kg)
≤15 30 mg td 2 × 5 mg inhalations 
(10 mg total) td 
(only in children 
aged ≥12 years)
15 - 23 45 mg td
24 - 40 60 mg td
>40 75 mg td
td = twice daily.
* Recommended duration of treatment is five days. Zanamivir is only registered for 
children ≥5 years of age.
